1.Minimally invasive surgery for remnant gastric cancer:a single-center retrospective study of treatment outcomes in Japan
Kenichi IWASAKI ; Edward BARROGA ; Yoichiro KANEKO ; Shohei KONDO ; Toru SAKURAI ; Erika YAMADA ; Masaya ENOMOTO ; Yota SHIMODA ; Kenta KASAHARA ; Hiroaki OSAKABE ; Junichi MAZAKI ; Hiroshi KUWABARA ; Junya OGUMA ; Hiroyuki KOGA ; Akishige KANAZAWA ; Yuichi NAKAGAWA
Journal of Minimally Invasive Surgery 2026;29(1):11-21
Purpose:
Surgical resection of remnant gastric cancer (RGC) is technically challenging and difficult. Minimally invasive surgery (MIS) has been adopted for various procedures, but reports of MIS for RGC remain limited. Herein, we report the surgical techniques and short-term outcomes of MIS for RGC.
Methods:
We conducted a retrospective cohort study involving 61 consecutive RGC patients who underwent open or minimally invasive (laparoscopic or robotic) total gastrectomy for potentially curable RGC at our institution (January 1999–August 2025). A propensity scorematched cohort was used for an exploratory evaluation of the safety and efficacy of MIS for RGC, focusing on feasibility rather than superiority over open surgery.
Results:
Of these 61 patients, 53 underwent open surgery and eight underwent MIS gastrectomy for RGC. The median age was 70 years. The cohort comprised 53 men and eight women. The initial procedure was open surgery in 58 patients and MIS in three patients.Propensity score matching showed significantly reduced intraoperative blood loss in the MIS group compared with the open surgery group (39 mL vs. 576 mL, p < 0.05), and significantly longer operation time in the MIS group (352 minutes vs. 297 minutes, p < 0.05). Postoperative hospital stay was significantly shorter in the MIS group (12 days vs. 17 days, p < 0.05). The incidence of postoperative pancreatic fistula was lower in the MIS group, although not significantly different (0% vs. 16.7%).
Conclusion
MIS, including robotic gastrectomy, is feasible and safe for RGC, with potential perioperative benefits requiring multicenter validation.
2.Prognostic impact of the number of resected pelvic nodes in endometrial cancer: Japanese Gynecologic Oncology Group Study JGOG2043 post hoc analysis
Yosuke KONNO ; Michinori MAYAMA ; Kazuhiro TAKEHARA ; Yoshihito YOKOYAMA ; Jiro SUZUKI ; Nobuyuki SUSUMU ; Kenichi HARANO ; Satoshi NAKAGAWA ; Toru NAKANISHI ; Wataru YAMAGAMI ; Kosuke YOSHIHARA ; Hiroyuki NOMURA ; Aikou OKAMOTO ; Daisuke AOKI ; Hidemichi WATARI
Journal of Gynecologic Oncology 2025;36(1):e3-
Objective:
This study aimed to determine whether the number of resected pelvic lymph nodes (PLNs) affects the prognosis of endometrial cancer (EC) patients at post-operative risk of recurrence.
Methods:
JGOG2043 was a randomized controlled trial to assess the efficacy of three chemotherapeutic regimens as adjuvant therapy in EC patients with post-operative recurrent risk. A retrospective analysis was conducted on 250 patients who underwent pelvic lymphadenectomy alone in JGOG2043. The number of resected and positive nodes and other clinicopathologic risk factors for survival were retrieved.
Results:
There were 83 patients in the group with less than 20 PLNs removed (group A), while 167 patients had 20 or more PLNs removed (group B). There was no significant difference in patients’ backgrounds between the two groups, and the rate of lymph node metastasis was not significantly different. There was a trend toward fewer pelvic recurrences in group B compared with group A (3.5% vs. 9.6%; p=0.050). Although Kaplan-Meier analysis showed no statistically significant difference in survival rates between the two groups (5-year overall survival [OS]=90.3% vs. 84.3%; p=0.199), multivariate analysis revealed that resection of 20 or more nodes is one of the independent prognostic factors (hazard ratio=0.49; 95% confidence interval=0.24–0.99; p=0.048), as well as surgical stage, high-risk histology, and advanced age for OS.
Conclusion
Resection of 20 or more PLNs was associated with improved pelvic control and better survival outcomes in EC patients at risk of recurrence who underwent pelvic lymphadenectomy alone and were treated with adjuvant chemotherapy.
3.Prognostic impact of the number of resected pelvic nodes in endometrial cancer: Japanese Gynecologic Oncology Group Study JGOG2043 post hoc analysis
Yosuke KONNO ; Michinori MAYAMA ; Kazuhiro TAKEHARA ; Yoshihito YOKOYAMA ; Jiro SUZUKI ; Nobuyuki SUSUMU ; Kenichi HARANO ; Satoshi NAKAGAWA ; Toru NAKANISHI ; Wataru YAMAGAMI ; Kosuke YOSHIHARA ; Hiroyuki NOMURA ; Aikou OKAMOTO ; Daisuke AOKI ; Hidemichi WATARI
Journal of Gynecologic Oncology 2025;36(1):e3-
Objective:
This study aimed to determine whether the number of resected pelvic lymph nodes (PLNs) affects the prognosis of endometrial cancer (EC) patients at post-operative risk of recurrence.
Methods:
JGOG2043 was a randomized controlled trial to assess the efficacy of three chemotherapeutic regimens as adjuvant therapy in EC patients with post-operative recurrent risk. A retrospective analysis was conducted on 250 patients who underwent pelvic lymphadenectomy alone in JGOG2043. The number of resected and positive nodes and other clinicopathologic risk factors for survival were retrieved.
Results:
There were 83 patients in the group with less than 20 PLNs removed (group A), while 167 patients had 20 or more PLNs removed (group B). There was no significant difference in patients’ backgrounds between the two groups, and the rate of lymph node metastasis was not significantly different. There was a trend toward fewer pelvic recurrences in group B compared with group A (3.5% vs. 9.6%; p=0.050). Although Kaplan-Meier analysis showed no statistically significant difference in survival rates between the two groups (5-year overall survival [OS]=90.3% vs. 84.3%; p=0.199), multivariate analysis revealed that resection of 20 or more nodes is one of the independent prognostic factors (hazard ratio=0.49; 95% confidence interval=0.24–0.99; p=0.048), as well as surgical stage, high-risk histology, and advanced age for OS.
Conclusion
Resection of 20 or more PLNs was associated with improved pelvic control and better survival outcomes in EC patients at risk of recurrence who underwent pelvic lymphadenectomy alone and were treated with adjuvant chemotherapy.
4.Prognostic impact of the number of resected pelvic nodes in endometrial cancer: Japanese Gynecologic Oncology Group Study JGOG2043 post hoc analysis
Yosuke KONNO ; Michinori MAYAMA ; Kazuhiro TAKEHARA ; Yoshihito YOKOYAMA ; Jiro SUZUKI ; Nobuyuki SUSUMU ; Kenichi HARANO ; Satoshi NAKAGAWA ; Toru NAKANISHI ; Wataru YAMAGAMI ; Kosuke YOSHIHARA ; Hiroyuki NOMURA ; Aikou OKAMOTO ; Daisuke AOKI ; Hidemichi WATARI
Journal of Gynecologic Oncology 2025;36(1):e3-
Objective:
This study aimed to determine whether the number of resected pelvic lymph nodes (PLNs) affects the prognosis of endometrial cancer (EC) patients at post-operative risk of recurrence.
Methods:
JGOG2043 was a randomized controlled trial to assess the efficacy of three chemotherapeutic regimens as adjuvant therapy in EC patients with post-operative recurrent risk. A retrospective analysis was conducted on 250 patients who underwent pelvic lymphadenectomy alone in JGOG2043. The number of resected and positive nodes and other clinicopathologic risk factors for survival were retrieved.
Results:
There were 83 patients in the group with less than 20 PLNs removed (group A), while 167 patients had 20 or more PLNs removed (group B). There was no significant difference in patients’ backgrounds between the two groups, and the rate of lymph node metastasis was not significantly different. There was a trend toward fewer pelvic recurrences in group B compared with group A (3.5% vs. 9.6%; p=0.050). Although Kaplan-Meier analysis showed no statistically significant difference in survival rates between the two groups (5-year overall survival [OS]=90.3% vs. 84.3%; p=0.199), multivariate analysis revealed that resection of 20 or more nodes is one of the independent prognostic factors (hazard ratio=0.49; 95% confidence interval=0.24–0.99; p=0.048), as well as surgical stage, high-risk histology, and advanced age for OS.
Conclusion
Resection of 20 or more PLNs was associated with improved pelvic control and better survival outcomes in EC patients at risk of recurrence who underwent pelvic lymphadenectomy alone and were treated with adjuvant chemotherapy.
5.Prognostic significance of para-aortic node metastasis in endometrial cancer:Japanese Gynecologic Oncology Group Study JGOG2043 post hoc analysis
Yosuke KONNO ; Michinori MAYAMA ; Kazuhiro TAKEHARA ; Yoshihito YOKOYAMA ; Jiro SUZUKI ; Nobuyuki SUSUMU ; Kenichi HARANO ; Satoshi NAKAGAWA ; Toru NAKANISHI ; Wataru YAMAGAMI ; Kosuke YOSHIHARA ; Hiroyuki NOMURA ; Aikou OKAMOTO ; Daisuke AOKI ; Hidemichi WATARI
Journal of Gynecologic Oncology 2025;36(4):e57-
Objective:
This study aimed to assess the prognostic significance of para-aortic lymphadenectomy (PALX) and para-aortic lymph node metastasis in endometrial cancer (EC) patients at risk of post-operative recurrence.
Methods:
Japanese Gynecologic Oncology Group (JGOG) 2043 was a randomized controlled trial assessing the efficacy of adjuvant chemotherapy in EC patients at risk for postoperative recurrence. A retrospective analysis included patients who underwent pelvic lymphadenectomy (PLX) alone or both PLX and PALX in JGOG2043. Data on positive lymph nodes and other clinicopathological risk factors were collected.
Results:
PLX and PALX were performed on 402 patients, while PLX alone was conducted on 250 patients. Evaluating the effect of PALX on survival was challenging through a comparison of the outcomes of the 2 cohorts since PALX was predominantly administered to higher-risk patients. Patients with 2 or more metastases in para-aortic nodes exhibited significantly poorer overall survival than those with no or 1 metastasis, respectively (p<0.001, p=0.031).Multivariate analysis revealed that 2 or more metastases in para-aortic nodes is independent risk factors for disease-free survival (hazard ratio [HR]=1.72; 95% confidence interval [CI]=1.10–2.72; p=0.019) and are marginally significant for overall survival (HR=1.58; 95% CI=0.92–2.72; p=0.096) compared to no or a single metastasis.
Conclusion
The clinical relevance of PALX was challenging to evaluate in the JGOG2043 cohort; however, the presence of 2 or more para-aortic node metastases was identified as an independent unfavorable prognostic factor in EC patients at risk of recurrence.
6.Clinical meaning of sarcopenia in patients undergoing endoscopic treatment
Hiroyuki HISADA ; Yosuke TSUJI ; Hikaru KURIBARA ; Ryohei MIYATA ; Kaori OSHIO ; Satoru MIZUTANI ; Hideki NAKAGAWA ; Rina CHO ; Nobuyuki SAKUMA ; Yuko MIURA ; Hiroya MIZUTANI ; Daisuke OHKI ; Seiichi YAKABI ; Yu TAKAHASHI ; Yoshiki SAKAGUCHI ; Naomi KAKUSHIMA ; Nobutake YAMAMICHI ; Mitsuhiro FUJISHIRO
Clinical Endoscopy 2024;57(4):446-453
With increasing global life expectancy, the significance of geriatric assessment parameters has increased. Sarcopenia is a crucial assessment parameter and is defined as the age-related loss of muscle mass and strength. Sarcopenia is widely acknowledged as a risk factor for postoperative complications in diverse advanced malignancies and has a detrimental effect on the long-term prognosis. While most studies have primarily concentrated on the correlation between sarcopenia and advanced cancer, more recent investigations have focused on the relationship between sarcopenia and early-stage cancer. Endoscopic submucosal dissection (ESD), which is less invasive than surgical intervention, is extensively employed in the management of early-stage cancer, although it is associated with complications such as bleeding and perforation. In recent years, several reports have revealed the adverse consequences of sarcopenia in patients with early-stage cancer undergoing ESD. This literature review briefly summarizes the recent studies on the association between sarcopenia and ESD.
7.Phase I/II prospective clinical trial for the hybrid of intracavitary and interstitial brachytherapy for locally advanced uterine cervical cancer
Naoya MURAKAMI ; Miho WATANABE ; Takashi UNO ; Shuhei SEKII ; Kayoko TSUJINO ; Takahiro KASAMATSU ; Yumiko MACHITORI ; Tomomi AOSHIKA ; Shingo KATO ; Hisako HIROWATARI ; Yuko KANEYASU ; Tomio NAKAGAWA ; Hitoshi IKUSHIMA ; Ken ANDO ; Masumi MURATA ; Ken YOSHIDA ; Hiroto YOSHIOKA ; Kazutoshi MURATA ; Tatsuya OHNO ; Noriyuki OKONOGI ; Anneyuko I. SAITO ; Mayumi ICHIKAWA ; Takahito OKUDA ; Keisuke TSUCHIDA ; Hideyuki SAKURAI ; Ryoichi YOSHIMURA ; Yasuo YOSHIOKA ; Atsunori YOROZU ; Naonobu KUNITAKE ; Hiroyuki OKAMOTO ; Koji INABA ; Tomoyasu KATO ; Hiroshi IGAKI ; Jun ITAMI
Journal of Gynecologic Oncology 2023;34(3):e24-
Objective:
The purposes of this trial were to demonstrate the feasibility and effectiveness of the hybrid of intracavitary and interstitial brachytherapy (HBT) for locally advanced cervical cancer patients in the phase I/II prospective clinical trial.
Methods:
Patients with FIGO stage IB2-IVA uterine cervical cancer pretreatment width of which was ≥5 cm measured by magnetic resonance imaging were eligible for this clinical trial. The protocol therapy included 30–30.6 Gy in 15–17 fractions of whole pelvic radiotherapy concurrent with weekly CDDP, followed by 24 Gy in 4 fractions of HBT and pelvic radiotherapy with a central shield up to 50–50.4 Gy in 25–28 fractions. The primary endpoint of phase II part was 2-year pelvic progression-free survival (PPFS) rate higher than historical control of 64%.
Results:
Between October 2015 and October 2019, 73 patients were enrolled in the initial registration and 52 patients proceeded to the secondary registration. With the median follow-up period of 37.3 months (range, 13.9–52.9 months), the 2- PPFS was 80.7% (90% confidence interval [CI]=69.7%–88%). Because the lower range of 90% CI of 2-year PPFS was 69.7%, which was higher than the historical control ICBT data of 64%, therefore, the primary endpoint of this study was met.
Conclusion
The effectiveness of HBT were demonstrated by a prospective clinical study. Because the dose goal determined in the protocol was lower than 85 Gy, there is room in improvement for local control. A higher dose might have been needed for tumors with poor responses.
9.How to Develop Human Resources in Cardiovascular Surgery : Investigation about the Gap between Ideal and Reality No.12
Koki ETO ; Yuichiro KISHIMOTO ; Hiromi WADA ; Hiromi ARASE ; Hiroyuki KURAZUMI ; Yuzi KODAMA ; Sayako NAKAGAWA ; Taisuke NAKAYAMA
Japanese Journal of Cardiovascular Surgery 2019;48(4):4-U1-4-U3
We investigated the training system of a young cardiovascular surgeon in Japan. We presented the result of surveillance at the 49th Annual Meeting of the Japanese Society for Cardiovascular Surgery 2019, and report here the summary.
10.Need for peri-operative weight loss among obese colorectal cancer patients
Hiromi NAKAGAWA ; Kiyoji TANAKA ; Hiroyuki SASAI ; Yuji NISHIZAWA ; Masaaki ITO
Japanese Journal of Physical Fitness and Sports Medicine 2018;67(2):147-155
Colorectal cancer patients account for the largest proportion of total cancer patients in Japan. With an increase in its surgical cases and relatively higher five-year survival rate, the number of cancer survivors is expected to be increasing. Therefore, primary prevention, surgical therapy and recurrence prevention for colorectal cancer are public health priorities in Japan. General and abdominal obesity (Not only abdominal but also general obesity) are risk factors for colorectal cancer. In addition, accumulated abdominal fat can extend time spent in surgery by hindering operative procedures and surgical field expansion. These factors raise the risk of postoperative complications such as bleeding and surgical site infection, which eventually leads to increased medical expenses. Physical activity is one of protective factors for colorectal cancer. Recent studies showed that exercise intervention in cancer survivors reduces the cancer recurrence risk. Furthermore, it has been suggested that exercise interventions are effective in reducing fatigue, improving immune function, and maintaining physical function. However, the effectiveness of preoperative exercise intervention aimed at reducing weight in colorectal cancer patients remains unknown. In this review article, we discuss necessity for peri-operative weight loss among obese colorectal cancer patients.


Result Analysis
Print
Save
E-mail